BFLY: Breakaway Gap detected on 19 Jun 2026

BFLY has triggered a breakaway gap pattern with a structure score of 15.0 and breakout score of 13.0, indicating solid pattern integrity. Current price sits at $8.90, just below resistance at $8.94. The stock has surged 117% over one month and trades at RSI of 84.59—overbought territory. Volume exploded to 58.97M shares (7.78x average), confirming aggressive breakout participation. Key support lies at $6.14. The overall score of 78 reflects a high-quality technical setup despite the overbought conditions.

On June 18, 2026, Butterfly announced that Midjourney Medical's full-body imaging system incorporates 40 Butterfly Ultrasound-on-Chip modules licensed under a co-development agreement, with the deal worth up to $74 million. This catalyst drove a 30%+ intraday spike on June 18. The timing aligns perfectly with the breakaway gap—institutional and retail positioning ahead of this deal announcement likely fueled the pattern. Fundamentally, Q1 2026 revenue reached $26.53M (up from $21.23M year-over-year), with net loss narrowing to $12.68M from $13.97M. However, the stock trades at 12.5x P/S versus 2.8x for the medical equipment industry, suggesting premium valuation on growth expectations.

A successful breakaway gap confirmation targets $9.40 conservatively based on measured move analysis. The pattern suggests closure and consolidation above $8.94 resistance, with volume need sustaining above 20-30M shares daily to validate continuation. Invalidation occurs at support of $6.14—a close below this level negates the breakout thesis. Win probability of 54.53% indicates marginal edge; the $1.26 upside to target versus $2.76 risk to support delivers unfavorable 1:2.2 reward-to-risk on the conservative case.

Critical warnings: RSI at 84.59 signals extreme overbought conditions—mean reversion pullback is statistically probable. The stock's beta of 2.45 means it will amplify downside volatility in any market correction. Healthcare sector trades in bearish regime (score -0.17), opposing the stock's rally. Valuation is stretched at 12.5x sales with no profitability path in the next three years per analyst forecasts. Recent insider selling (Form 4 filings on June 4, 8) suggests management caution. Midjourney partnership provides upside, but execution risk remains—prototype stages often disappoint in clinical adoption.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.